Tozho

Executive Summary

Tozho is a San Francisco-based biotechnology company developing a novel platform for regenerative medicine using engineered extracellular vesicles (EVs). Its technology combines immune-evasive properties with pro-healing enzymes to create cell-free therapies that target chronic, non-healing wounds—a condition affecting millions globally and representing a significant unmet medical need. By leveraging the natural intercellular communication capabilities of EVs, Tozho aims to deliver precise, localized treatment that promotes tissue repair and reduces inflammation, potentially overcoming the limitations of existing wound care modalities. The company operates in the early preclinical stage, with no disclosed funding rounds or clinical milestones to date. However, its differentiated approach in the rapidly advancing EV therapeutics space positions it for potential partnerships and investment. Tozho's platform could address not only wound healing but also broader inflammatory and fibrotic diseases, though near-term focus remains on proof-of-concept studies. The success of the company hinges on advancing its lead candidates into preclinical development and securing capital to support translational research.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round50% success
• Q4 2026Preclinical Proof-of-Concept Data Release40% success
• Q1 2027Partnership with Wound Care or Pharmaceutical Company30% success